Nathan J. Dowden serves as the President and Chief Operating Officer at Entrada Therapeutics Inc., a position he has held since joining the company in 2020. With a robust background in biotechnology and pharmaceuticals, Dowden has been instrumental in steering Entrada's strategic direction and operational execution. His leadership has been pivotal in advancing the company's mission to develop transformative therapies for patients with devastating diseases. Prior to his role at Entrada Therapeutics, Dowden held several key positions in the industry. He was the Chief Operating Officer at Translate Bio, where he played a significant role in the company's growth and eventual acquisition by Sanofi. Before that, he spent over a decade at Shire, now part of Takeda, in various senior roles, including Vice President of Global Gene Therapy. His extensive experience in both operational and strategic capacities has equipped him with a deep understanding of the challenges and opportunities in the biotech sector. At Entrada Therapeutics, Dowden oversees the company's day-to-day operations and works closely with the executive team to ensure the successful development and commercialization of its therapeutic pipeline. His achievements include leading the company through several key milestones, such as the advancement of clinical trials and the establishment of strategic partnerships. Under his guidance, Entrada continues to make significant strides in the field of RNA-based therapeutics, aiming to bring innovative treatments to patients in need.